A worldwide phase 3 clinical trial of ASP‐1929, an anti‐epidermal growth factor receptor (EGFR) antibody cetuximab conjugated with IR700, is ongoing in patients with recurrent or inoperable head and neck cancer (NCT03769506). This evidence concerns the gene EGFR and head and neck cancer.